nach oben

Erschienen in:

30.07.2018 | Review

Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis

verfasst von: Neide Tomimura Costa, Tatiana Mayumi Veiga Iriyoda, Daniela Frizon Alfieri, Andréa Name Colado Simão, Isaias Dichi

Erschienen in: Inflammopharmacology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Nitro-oxidative stress plays a central role in the pathogenesis of rheumatoid arthritis (RA) and several articles show correlation with disease activity. However, the influence and mechanisms by which disease-modifying antirheumatic drugs (DMARDs) may interfere with nitro-oxidative stress are poorly understood.

Objective

To show the available data on the effect of the DMARDs on the nitro-oxidative stress in RA patients.

Methods

A bibliographic search was carried out in the electronic databases PUBMED, Lilacs, Scientific Electronic Library Online (SCIELO), and Science Direct and the research was limited to human studies, independently of the publication date.

Results

Most studies were performed with infliximab (IFX, 4 articles), tocilizumab (TCZ, 3 articles) and methotrexate (MTX, 2 articles). MTX and leflunomide showed similar results with reduction of nitric oxide. The studies with TCZ verified a marked decrease of reactive oxygen and nitrogen species. Most studies with IFX found a reduction of protein oxidation, evaluated by protein carbonyl measurement. In the present review, the most remarkable results were observed with the increase of the antioxidant defenses through several markers and antioxidant systems. The only study with etanercept showed very similar results to those obtained with MTX, with decreased pentosidine and oxidative DNA damage.

Conclusions

The majority of the studies reported in this work showed an improvement in the redox state, which could be related to success of the therapy. Thus, oxidative and nitrosative stress markers may be useful to early evaluate the response of DMARDs in patients with RA.

Ahmadinejad F, Geir Møller S, Hashemzadeh-Chaleshtori M et al (2017) Molecular mechanisms behind free radical scavengers function against oxidative stress. Antioxidants 6:51. https://doi.org/10.3390/antiox6030051 CrossRefPubMedCentral

Altindag O, Karakoc M, Kocyigit A et al (2007) Increased DNA damage and oxidative stress in patients with rheumatoid arthritis. Clin Biochem 40:167–171. https://doi.org/10.1016/j.clinbiochem.2006.10.006 CrossRefPubMed

Biniecka M, Kennedy A, Ng CT et al (2011) Successful tumour necrosis factor (TNF) blocking therapy suppresses oxidative stress and hypoxia-induced mitochondrial mutagenesis in inflammatory arthritis. Arthritis Res Ther 13:R121. https://doi.org/10.1186/ar3424 CrossRefPubMedPubMedCentral

Biswas SK (2016) Does the interdependence between oxidative stress and inflammation explain the antioxidant paradox? Oxid Med Cell Longev 2016:17–19. https://doi.org/10.1155/2016/5698931 CrossRef

Blanco L, Ling S, Holoshitz J (2014) Oxidative stress in rheumatoid arthritis. In: Role of oxidative stress in chronic diseases. CRC Press, Boca Raton, pp 481–500CrossRef

Cacciapaglia F, Grazia Anelli M, Rizzo D et al (2016) Effective tumour necrosis factor-blocking therapy reduces reactive oxygen metabolite level in rheumatoid arthritis. J Int Med Res 44:28–32. https://doi.org/10.1177/0300060515593227 CrossRefPubMedPubMedCentral

Casado MF, Cecchini AL, Simão ANC et al (2007) Free radical-mediated pre-hemolytic injury in human red blood cells subjected to lead acetate as evaluated by chemiluminescence. Food Chem Toxicol 45:945–952. https://doi.org/10.1016/j.fct.2006.12.001 CrossRefPubMed

Coimbra IB, Jimenez SA, Hawkins DF et al (2004) Hypoxia inducible factor-1 alpha expression in human normal and osteoarthritic chondrocytes. Osteoarthr Cartil 12:336–345. https://doi.org/10.1016/j.joca.2003.12.005 CrossRefPubMed

Costa NT, Veiga Iriyoda TM, Kallaur AP et al (2016) Influence of insulin resistance and TNF-alfa on the inflammatory process, oxidative stress, and disease activity in patients with rheumatoid arthritis. Oxid Med Cell Longev 2016:8962763. https://doi.org/10.1155/2016/8962763 CrossRefPubMedPubMedCentral

den Broeder AA, Wanten GJA, Oyen WJG et al (2003) Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis. J Rheumatol 30:232–237

Desai PB, Manjunath S, Kadi S et al (2010) Oxidative stress and enzymatic antioxidant status in rheumatoid arthritis: a case control study. Eur Rev Med Pharmacol Sci 14:959–967PubMed

Elkayam O, Yaron I, Shirazi I et al (2003) Active leflunomide metabolite inhibits interleukin 1beta, tumour necrosis factor alpha, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 62:440–443. https://doi.org/10.1136/ard.62.5.440 CrossRefPubMedPubMedCentral

Feijóo M, Túnez I, Tasset I et al (2009) Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. Pharmacology 83:211–216. https://doi.org/10.1159/000200022 CrossRefPubMed

Fox RI, Herrmann ML, Frangou CG et al (1999) Mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 93:198–208. https://doi.org/10.1006/clim.1999.4777 CrossRefPubMed

Frijhoff J, Winyard PG, Zarkovic N et al (2015) Clinical relevance of biomarkers of oxidative stress. Antioxid Redox Signal 23:1144–1170. https://doi.org/10.1089/ars.2015.6317 CrossRefPubMedPubMedCentral

Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A et al (2009) Short-term effect of anti-TNF-alpha therapy on nitric oxide production in patients with severe rheumatoid arthritis. Clin Exp Rheumatol 27:452–458PubMed

Gringhuis SI, Leow A, Papendrecht-van der Voort EAM et al (2000) Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J Immunol 164:2170–2179. https://doi.org/10.4049/jimmunol.164.4.2170 CrossRefPubMed

Hassan SZ, Gheita TA, Kenawy SA et al (2011) Oxidative stress in systemic lupus erythematosus and rheumatoid arthritis patients: relationship to disease manifestations and activity. Int J Rheum Dis 14:325–331. https://doi.org/10.1111/j.1756-185X.2011.01630.x CrossRefPubMed

Herman S, Zurgil N, Langevitz P, Ehrenfeld M, Deutsch M (2008) Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin Exp Rheumatol 26(2):317–323PubMed

Hirao M, Yamasaki N, Oze H et al (2012) Serum level of oxidative stress marker is dramatically low in patients with rheumatoid arthritis treated with tocilizumab. Rheumatol Int 32:4041–4045. https://doi.org/10.1007/s00296-011-2135-0 CrossRefPubMed

Hitchon CA, El-Gabalawy HS (2004) Oxidation in rheumatoid arthritis. Arthritis Res Ther 6:265–278. https://doi.org/10.1186/ar1447 CrossRefPubMedPubMedCentral

Hochberg M, Silman A, Smolen J et al (2015) Rheumatology, Sixth edn. Elsevier Mosby, Philadelphia

Kageyama Y, Takahashi M, Nagafusa T et al (2007) Methotrexate reduces the levels of pentosidine and 8-hydroxy-deoxy guanosine in patients with rheumatoid arthritis. Mod Rheumatol 17:398–402. https://doi.org/10.1007/s10165-007-0607-6 CrossRefPubMed

Kageyama Y, Takahashi M, Ichikawa T et al (2008a) Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. Clin Exp Rheumatol 26:73–80PubMed

Kageyama Y, Takahashi M, Nagafusa T et al (2008b) Etanercept reduces the oxidative stress marker levels in patients with rheumatoid arthritis. Rheumatol Int 28:245–251. https://doi.org/10.1007/s00296-007-0419-1 CrossRefPubMed

Kizaki K, Yamashita F, Hayashi T, Funakoshi N (2016) Infliximab is equivalently suppressing oxidative stress compared to tocilizumab among well-controlled patients with rheumatoid arthritis. Int J Rheum Dis. https://doi.org/10.1111/1756-185X.12972 CrossRefPubMed

Lemarechal H, Allanore Y, Chenevier-Gobeaux C et al (2006) Serum protein oxidation in patients with rheumatoid arthritis and effects of infliximab therapy. Clin Chim Acta 372:147–153. https://doi.org/10.1016/j.cca.2006.04.002 CrossRefPubMed

Listing J, Kekow J, Manger B et al (2015) Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Ann Rheum Dis 74:415–421. https://doi.org/10.1136/annrheumdis-2013-204021 CrossRefPubMed

Myasoedova E, Crowson CS, Kremers HM et al (2010) Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62:1576–1582. https://doi.org/10.1002/art.27425 CrossRefPubMedPubMedCentral

Nakajima A, Aoki Y, Shibata Y et al (2014) Identification of clinical parameters associated with serum oxidative stress in patients with rheumatoid arthritis. Mod Rheumatol 24:926–930. https://doi.org/10.3109/14397595.2014.891495 CrossRefPubMed

Ozkan Y, Yardým-Akaydýn S, Sepici A et al (2007) Oxidative status in rheumatoid arthritis. Clin Rheumatol 26:64–68. https://doi.org/10.1007/s10067-006-0244-z CrossRefPubMed

Phillips DC, Woollard KJ, Griffiths HR (2003) The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol 138:501–511. https://doi.org/10.1038/sj.bjp.0705054 CrossRefPubMedPubMedCentral

Pufe T, Lemke A, Kurz B et al (2004) Mechanical overload induces VEGF in cartilage discs via hypoxia-inducible factor. Am J Pathol 164:185–192. https://doi.org/10.1016/S0002-9440(10)63109-4 CrossRefPubMedPubMedCentral

Quiñonez-Flores CM, González-Chávez SA, Del Río Nájera D, Pacheco-Tena C (2016) Oxidative stress relevance in the pathogenesis of the rheumatoid arthritis: a systematic review. Biomed Res Int 2016:6097417. https://doi.org/10.1155/2016/6097417 CrossRefPubMedPubMedCentral

Reddy SVB, Wanchu A, Khullar M et al (2005) Leflunomide reduces nitric oxide production in patients with active rheumatoid arthritis. Int Immunopharmacol 5:1085–1090. https://doi.org/10.1016/j.intimp.2004.11.013 CrossRefPubMed

Ruiz-Limón P, Ortega R, Arias de la Rosa I et al (2017) Tocilizumab improves the proatherothrombotic profile of rheumatoid arthritis patients modulating endothelial dysfunction, NETosis, and inflammation. Transl Res 183:87–103. https://doi.org/10.1016/j.trsl.2016.12.003 CrossRefPubMed

Schalkwijk J, van der Berg W, van de Putte L, Joosten L (1986) An experimental model for hydrogen peroxide–induced tissue damage. Effects of a single inflammatory mediator on (peri)articular tissues. Arthritis Rheum 29:532–538. https://doi.org/10.1002/art.1780290411 CrossRefPubMed

Shahmohamadnejad S, Vaisi-Raygani A, Shakiba Y et al (2015) Association between butyrylcholinesterase activity and phenotypes, paraoxonase192 rs662 gene polymorphism and their enzymatic activity with severity of rheumatoid arthritis: correlation with systemic inflammatory markers and oxidative stress, preliminary. Clin Biochem 48:63–69. https://doi.org/10.1016/j.clinbiochem.2014.08.016 CrossRefPubMed

Sies H (2015) Oxidative stress: a concept in redox biology and medicine. Redox Biol 4:180–183. https://doi.org/10.1016/j.redox.2015.01.002 CrossRefPubMedPubMedCentral

Spurlock C III, Aune ZT, Tossberg JT et al (2011) Increased sensitivity to apoptosis induced by methotrexate is mediated by Jun N-terminal kinase. Arthritis Rheum 63:2606–2616. https://doi.org/10.1002/art.30457.Increased CrossRefPubMedPubMedCentral

Taysi S, Polat F, Gul M et al (2002) Lipid peroxidation, some extracellular antioxidants, and antioxidant enzymes in serum of patients with rheumatoid arthritis. Rheumatol Int 21:200–204. https://doi.org/10.1007/s00296-001-0163-x CrossRefPubMed

Túnez I, Feijóo M, Huerta G et al (2007) The effect of infliximab on oxidative stress in chronic inflammatory joint disease. Curr Med Res Opin 23:1259–1267. https://doi.org/10.1185/030079907X187955 CrossRefPubMed

Weinblatt ME, Keystone EC, Furst DE et al (2003) Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45. https://doi.org/10.1002/art.10697 CrossRefPubMed

Wruck CJ, Fragoulis A, Gurzynski A et al (2011) Role of oxidative stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann Rheum Dis 70:844–850. https://doi.org/10.1136/ard.2010.132720 CrossRefPubMed

Titel: Influence of disease-modifying antirheumatic drugs on oxidative and nitrosative stress in patients with rheumatoid arthritis
verfasst von: Neide Tomimura Costa
Tatiana Mayumi Veiga Iriyoda
Daniela Frizon Alfieri
Andréa Name Colado Simão
Isaias Dichi
Publikationsdatum: 30.07.2018
Verlag: Springer International Publishing
Erschienen in: Inflammopharmacology / Ausgabe 5/2018
Print ISSN: 0925-4692
Elektronische ISSN: 1568-5608
DOI: https://doi.org/10.1007/s10787-018-0514-9

Springer Medizin

Abstract

Background

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Essential oil from waste leaves of Curcuma longa L. alleviates skin inflammation

Inosine improves cognitive function and decreases aging-induced oxidative stress and neuroinflammation in aged female rats

Flavonoid quercetin–methotrexate combination inhibits inflammatory mediators and matrix metalloproteinase expression, providing protection to joints in collagen-induced arthritis

Polar extract of Curcuma longa protects cartilage homeostasis: possible mechanism of action

Regulatory effects of dexamethasone on NK and T cell immunity

Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers